Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lienert

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Therapeutische Umschau. Revue Therapeutique|October 21, 2004
[Uric acid and multiple sclerosis]H P Mattle, C Lienert, I Greeve
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 1999
Use of composite scores in the quantification of deterioration in multiple sclerosisC Lienert, J Lechner-Scott, D Schött, et al.
Der Nervenarzt|September 14, 1999
[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]C Zimmermann, E U Walther, N Goebels, et al.
Brain : a Journal of Neurology|January 5, 1999
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosisD Leppert, J Ford, G Stabler, et al.
European Journal of Neurology|February 26, 2020
Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatmentV von Wyl, B F Décard, P Benkert, et al.
European Journal of Neurology|October 26, 2005
Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosisC Weder, G M Baltariu, K A Wyler, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 13, 2015
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosisJ Kuhle, M Hardmeier, G Disanto, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Therapeutische Umschau. Revue Therapeutique|October 21, 2004
[Uric acid and multiple sclerosis]H P Mattle, C Lienert, I Greeve
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 1999
Use of composite scores in the quantification of deterioration in multiple sclerosisC Lienert, J Lechner-Scott, D Schött, et al.
Der Nervenarzt|September 14, 1999
[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]C Zimmermann, E U Walther, N Goebels, et al.
Brain : a Journal of Neurology|January 5, 1999
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosisD Leppert, J Ford, G Stabler, et al.
European Journal of Neurology|February 26, 2020
Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatmentV von Wyl, B F Décard, P Benkert, et al.
European Journal of Neurology|October 26, 2005
Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosisC Weder, G M Baltariu, K A Wyler, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 13, 2015
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosisJ Kuhle, M Hardmeier, G Disanto, et al.
Pageof 1